blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2981624

EP2981624 - METHODS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY AND PREDICTING RESPONSE TO CANCER TREATMENT [Right-click to bookmark this link]
Former [2016/06]METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
[2019/07]
StatusOpposition rejected
Status updated on  17.02.2023
Database last updated on 23.05.2026
FormerThe patent has been granted
Status updated on  15.11.2019
FormerGrant of patent is intended
Status updated on  29.01.2019
FormerExamination is in progress
Status updated on  01.09.2017
Most recent event   Tooltip17.02.2023Opposition rejectedpublished on 22.03.2023  [2023/12]
Applicant(s)For all designated states
Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108 / US
[2019/48]
Former [2016/06]For all designated states
Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108 / US
For all designated states
Abkevich, Victor
320 Wakara Way
Salt Lake City, Utah 84108 / US
For all designated states
Timms, Kirsten
320 Wakara Way
Salt Lake City, Utah 84108 / US
For all designated states
Gutin, Alexander
320 Wakara Way
Salt Lake City, Utah 84108 / US
Inventor(s)01 / ABKEVICH, Victor
320 Wakara Way
Salt Lake City Utah 84108 / US
02 / TIMMS, Kirsten
320 Wakara Way
Salt Lake City Utah 84108 / US
03 / GUTIN, Alexander
320 Wakara Way
Salt Lake City Utah 84108 / US
 [2016/06]
Representative(s)Pohlman, Sandra M., et al
df-mp Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
[N/P]
Former [2019/51]Hutter, Anton
Venner Shipley LLP
5 Stirling House
Stirling Road The Surrey Research Park
Guildford GU2 7RF / GB
Former [2016/06]Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Application number, filing date14779403.604.04.2014
[2016/06]
WO2014US33014
Priority number, dateUS201361809105P05.04.2013         Original published format: US 201361809105 P
US201361913762P09.12.2013         Original published format: US 201361913762 P
[2016/06]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014165785
Date:09.10.2014
Language:EN
[2014/41]
Type: A2 Application without search report 
No.:EP2981624
Date:10.02.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 09.10.2014 takes the place of the publication of the European patent application.
[2016/06]
Type: B1 Patent specification 
No.:EP2981624
Date:18.12.2019
Language:EN
[2019/51]
Search report(s)International search report - published on:KR09.10.2014
(Supplementary) European search report - dispatched on:EP28.10.2016
ClassificationIPC:C12Q1/6886
[2019/07]
CPC:
C12Q1/6886 (EP,US); A61K33/243 (EP,US); A61P1/04 (EP);
A61P15/00 (EP); A61P35/00 (EP); A61P43/00 (EP);
C12Q1/6827 (EP,US); C12Q1/6858 (EP,US); G16B20/20 (EP,US);
C12Q2600/106 (EP,US); C12Q2600/154 (US); C12Q2600/156 (EP,US);
G16B20/00 (EP,US) (-)
C-Set:
C12Q1/6827, C12Q2535/122, C12Q2537/143 (EP,US);
C12Q1/6858, C12Q2535/122, C12Q2537/143 (US,EP)
Former IPC [2016/06]C12Q1/68, G06F19/18, G01N33/15
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR BEURTEILUNG EINES MANGELS AN HOMOLOGER REKOMBINATION UND ZUR VORHERSAGE DER REAKTION AUF EINE KREBSTHERAPIE[2019/07]
English:METHODS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY AND PREDICTING RESPONSE TO CANCER TREATMENT[2019/07]
French:MÉTHODES DESTINÉES À ÉVALUER LE DÉFICIT DE RECOMBINAISON HOMOLOGUE ET PREDIRE LA REPONSE A UN TRAITEMENT CONTRE LE CANCER[2019/07]
Former [2016/06]VERFAHREN UND MATERIALIEN ZUR BEURTEILUNG EINES MANGELS AN HOMOLOGER REKOMBINATION
Former [2016/06]METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
Former [2016/06]MÉTHODES ET SUBSTANCES DESTINÉES À ÉVALUER LE DÉFICIT DE RECOMBINAISON HOMOLOGUE
Entry into regional phase22.10.2015National basic fee paid 
22.10.2015Search fee paid 
22.10.2015Designation fee(s) paid 
22.10.2015Examination fee paid 
Examination procedure22.10.2015Examination requested  [2016/06]
08.05.2017Amendment by applicant (claims and/or description)
31.08.2017Despatch of a communication from the examining division (Time limit: M06)
12.02.2018Reply to a communication from the examining division
13.06.2018Despatch of a communication from the examining division (Time limit: M04)
27.09.2018Reply to a communication from the examining division
30.01.2019Communication of intention to grant the patent
11.06.2019Fee for grant paid
11.06.2019Fee for publishing/printing paid
11.06.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19216740.1  / EP3693475
Opposition(s)Opponent(s)01  15.09.2020  17.09.2020  ADMISSIBLE
Siemens Healthcare GmbH
Henkestraße 127
91052 Erlangen / DE
Opponent's representative
Lier, Simone
Siemens Healthcare Diagnostics Products GmbH
Postfach 22 16 34
80506 München / DE
 [2022/31]
Former [2020/43]
Opponent(s)01  15.09.2020  17.09.2020  ADMISSIBLE
NEO New Oncology GmbH
Gottfried-Hagen-Strasse 20
51105 Köln / DE
Opponent's representative
Lier, Simone
Siemens Healthcare Diagnostics Products GmbH
Postfach 22 16 34
80506 München / DE
02.10.2020Invitation to proprietor to file observations on the notice of opposition
11.02.2021Reply of patent proprietor to notice(s) of opposition
20.07.2022Cancellation of oral proceeding that was planned for 12.09.2022
12.09.2022Date of oral proceedings
04.11.2022Date of despatch of rejection of opposition
14.11.2022Legal effect of rejection of opposition [2023/12]
Fees paidRenewal fee
30.03.2016Renewal fee patent year 03
10.04.2017Renewal fee patent year 04
09.04.2018Renewal fee patent year 05
08.04.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.04.2014
AL18.12.2019
CY18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MK18.12.2019
MT18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
LU04.04.2020
IS18.04.2020
BE30.04.2020
[2022/32]
Former [2022/27]HU04.04.2014
AL18.12.2019
CY18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MT18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
LU04.04.2020
IS18.04.2020
BE30.04.2020
Former [2021/12]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
LU04.04.2020
IS18.04.2020
BE30.04.2020
Former [2021/08]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
LU04.04.2020
IS18.04.2020
Former [2020/52]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
Former [2020/51]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
Former [2020/40]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
Former [2020/37]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/35]AL18.12.2019
CZ18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/32]AL18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/25]HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/23]LT18.12.2019
LV18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/22]LT18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/21]NO18.03.2020
Documents cited:Search[XYI] WO2012027224  (DANA FARBER CANCER INST INC et al.)
 [XPYI] WO2013130347  (CHILDRENS HOSPITAL CORP et al.)
 [XYI] WO2011160063  (MYRIAD GENETICS INC et al.) [X] 1,3,5-7,10,13 * p. 7, l. 12-29; p. 8, l. 8-10; p. 12, l. 31 - p. 13, l. 4; p. 14, l. 1-13; p. 16. l. 12 - p. 17, l. 5; p. 19, l. 9; claims 1, 31, 32; fig. 9 *[Y] 2,11,12 [I] 4,8,9,14,15
 [A] KR100925337  (MACROGEN INC et al.)
 [XPYI]   ANONYMOUS: "Myriad's HRD Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study", 14 December 2013 (2013-12-14), XP055312045, Retrieved from the Internet [retrieved on 20161019]
 [YD]   T. POPOVA ET AL: "Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation", CANCER RESEARCH, 29 August 2012 (2012-08-29), XP055039519, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-1470

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-1470
 [A]   N. J. BIRKBAK ET AL: "Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents", CANCER DISCOVERY, vol. 2, no. 4, 22 March 2012 (2012-03-22), pages 366 - 375, XP055162779, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-11-0206

DOI:   http://dx.doi.org/10.1158/2159-8290.CD-11-0206
 [XPYI]   V ABKEVICH ET AL: "Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer", BRITISH JOURNAL OF CANCER, vol. 107, no. 10, 6 November 2012 (2012-11-06), pages 1776 - 1782, XP055085758, ISSN: 0007-0920, DOI: 10.1038/bjc.2012.451 [Y] 12 [I] 4,8,9,14,15

DOI:   http://dx.doi.org/10.1038/bjc.2012.451
 [XPYI]   ML TELLI ET AL: "Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)", CANCER RESEARCH, 15 December 2012 (2012-12-15), XP055312264, Retrieved from the Internet [retrieved on 20161019] [XP] 1,7,10 * the whole document *[Y] 2,11,12 [I] 3-6,8,9,13-15

DOI:   http://dx.doi.org/10.1158/0008-5472.SABCS12-PD09-04
 [YD]   MARIEKE A VOLLEBERGH ET AL: "Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHUSER-VERLAG, BA, vol. 69, no. 2, 16 September 2011 (2011-09-16), pages 223 - 245, XP019993251, ISSN: 1420-9071, DOI: 10.1007/S00018-011-0809-0 [YD] 2,11,12 * abstract; p. 4, 1st para.; p. 21, 1st para. *

DOI:   http://dx.doi.org/10.1007/s00018-011-0809-0
OppositionWO2012027224
 WO2011160063
   POPOVA, T. ET AL.: "Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation", CANCER RES, vol. 72, no. 21, 29 August 2012 (2012-08-29), pages 5454 - 5462, XP055341888, DOI: 10.1158/0008-5472.CAN-12-1470

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-1470
   BIRBAK, N.J. ET AL.: "Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents", CANCER DISCOVERY, vol. 2, 22 March 2012 (2012-03-22), pages 366 - 375, XP055162779, DOI: 10.1158/2159-8290.CD-11-0206

DOI:   http://dx.doi.org/10.1158/2159-8290.CD-11-0206
   ABKEVICH, A. ET AL.: "Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer", BRITISH JOURNAL OF CANCER, vol. 107, 9 October 2012 (2012-10-09), pages 1776 - 1782, XP055085758, DOI: 10.1038/bjc.2012.451

DOI:   http://dx.doi.org/10.1038/bjc.2012.451
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.